Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29362190.
- Also identified by DOI 10.1016/j.athoracsur.2017.09.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In patients with left ventricular assist device support and aspirin allergy, the choice of effective antiplatelet strategy remains a challenge. We compared the antithrombotic effect of clopidogrel vs ticagrelor in an LVAD patient with aspirin allergy by using a modified protocol of the thrombin generation test, accounting selectively for the platelet contribution on thrombin generation. Our results demonstrate enhanced antithrombotic efficacy offered by ticagrelor. Consistent with experimental results, the patient has passed more than 300 days without thromboembolic complications. This study provides additional mechanistic rationale supporting clinical evidence and opens the perspective to identify individual poor responsiveness to drugs by specifically evaluating drug-mediated platelet function.
Medical subject headings
- Aspirin
- Heart-Assist Devices
- Platelet Aggregation Inhibitors
- Postoperative Complications
- Thrombosis
- Ticlopidine
- Warfarin